Biotech stocks advanced for a fifth straight week in thin holiday trading. The gains, however, were more modest amid worries concerning the emergence of a new strain of coronavirus in the U.K.
The news flow of the week comprised mixed clinical trial readouts, COVID-19 drug and vaccine announcements, a few M&A announcements and a small-ticket IPO.
Gene therapy stocks uniQure N.V. (NASDAQ: QURE) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) came under pressure after the Food and Drug Administration placed their respective clinical programs on hold.
Here are the key catalysts for the week ahead:
Viatris Inc (NASDAQ: VTRS), which was formed following the merger of the erstwhile generic pharma company Mylan and Pfizer Inc.‘s (NYSE: PFE) Upjohn generic unit, awaits FDA approval for its BLA for MYL-1402O, a proposed biosimilar to Avastin from Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY). This is being developed in partnership with India’s Biocon. The PDUFA goal date is Dec. 27 (Sunday).
The FDA is scheduled to rule on Osmotica Pharmaceuticals PLC‘s (NASDAQ: OSMT) NDA for Ontinua (arbaclofen) ER for treating spasticity in patients with multiple sclerosis. The investigational asset had faced an earlier rejection in 2016 due to manufacturing issues at clinical trial sites. Following a resubmission, the FDA has set a PDUFA action date of Dec. 29 (Tuesday).
Proposed Regulatory Filings
Atara Biotherapeutics Inc (NASDAQ: ATRA): Rolling biologic license approval, or BLA, submission of tab-cel for Epstein-Barr virus-positive post-transplant disorder planned to be initiated by end of 2020, with finalization of the submission planned for the third quarter of 2021.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX): Submission of a supplemental new drug application for Trikafta is planned for the fourth quarter. Trikafta is a triple combination of elexacaftor, tezacaftor/ivacaftor and ivacaftor, in children, ages 6-11 years, with cystic fibrosis with certain mutations. It was approved for people, aged 12 years and older in late October.
Incyte Corporation (NASDAQ: INCY): A new drug application, or NDA, for ruxolitinib cream in atopic dermatitis is planned for the end of 2020.
Oyster Point Pharma Inc (NASDAQ: OYST): The company is on track to submit an NDA for OC-01 for dry eye disease in the fourth quarter.
Eyenovia Inc (NASDAQ: EYEN): An NDA submission for MicroStat (brand name: Mydcombi) for pharmacologic mydriasis is planned for the end of 2020.
Coherus Biosciences Inc (NASDAQ: CHRS): A BLA for the internally developed Humira biosimilar, CHS-1420, is expected by the end of 2020.
Stealth BioTherapeutics Corp (NASDAQ: MITO): An NDA submission for elamipretidein Barth syndrome is anticipated by year-end.
Cara Therapeutics Inc (NASDAQ: CARA): An NDA submission for Korsuva injection for the treatment of pruritus in hemodialysis patients, is planned for the fourth quarter.
Clinical Readouts — Pending Q4 Releases
RedHill Biopharma Ltd (NASDAQ: RDHL): Top-line data from the U.S. Phase 2 study of opaganib in 40 severe COVID-19 patients
Dynavax Technologies Corporation (NASDAQ: DVAX): Final immunogenicity data from the Phase 1 study of Heplisav-B in patients on hemodialysis
Immunic Inc (NASDAQ: IMUX): Phase 2 data for IMU-838 in primary sclerosing cholangitis
Altimmune Inc (NASDAQ: ALT): Results from this Phase 1b study NasoShield intranasal anthrax vaccine
Pending 2020 Year-End Releases
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX): Top-line proof-of-concept data from the Phase 2 study of Firdapse in spinal muscular atrophy type-3
Aprea Therapeutics Inc (NASDAQ: APRE): Top-line data from the Phase 3 study of eprenetapopt with Bristol-Myers Squibb Co‘s (NYSE: BMY) azacitidine as frontline therapy in HMA-naïve TP53 mutant myelodysplastic syndromes patients
Bellerophon Therapeutics Inc (NASDAQ: BLPH): Top-line data from the Phase 2 dose escalation study of INOpulse in pulmonary hypertension-sarcoidosis
Merus NV (NASDAQ: MRUS): Clinical update on the Phase 1 trial of MCLA-158 in patients with solid tumors
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE): Data from Cohort 4 of the Phase 1/2 study of investigational gene therapy DTX401 for glycogen storage disease Type Ia (a prophylactic steroid regimen is added to the same dose as used for Cohort 2 and 3)
IPO Quiet Period Expiries
Photo source: Pexels
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.